BR112018071991A2 - forma de cristal da dapaglifozina e método para a preparação e uso da mesma - Google Patents

forma de cristal da dapaglifozina e método para a preparação e uso da mesma

Info

Publication number
BR112018071991A2
BR112018071991A2 BR112018071991-9A BR112018071991A BR112018071991A2 BR 112018071991 A2 BR112018071991 A2 BR 112018071991A2 BR 112018071991 A BR112018071991 A BR 112018071991A BR 112018071991 A2 BR112018071991 A2 BR 112018071991A2
Authority
BR
Brazil
Prior art keywords
crystal form
preparation
dapaglifozine
ethoxymethylphenylmethane
glucopyranose
Prior art date
Application number
BR112018071991-9A
Other languages
English (en)
Inventor
Li Xiang
He Lei
Yu Jun
Wang Jinjia
Du Zuyin
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. filed Critical Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Publication of BR112018071991A2 publication Critical patent/BR112018071991A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)

Abstract

a presente invenção refere-se a uma nova forma de cristal da dapaglifozina e um método para a preparação e o uso da mesma. de forma específica, são descritas uma forma de cristal e de 2-cloro-5-(ß-d-glucopiranose-1-il)-4'-etioximetilfenilmetano e um método de preparação para a mesma, e uma composição farmacêutica que contém uma quantidade terapeuticamente efetiva da forma de cristal e o uso da mesma no tratamento do diabetes do tipo ii.
BR112018071991-9A 2016-05-24 2017-05-22 forma de cristal da dapaglifozina e método para a preparação e uso da mesma BR112018071991A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610347924 2016-05-24
CN201610347924.8 2016-05-24
PCT/CN2017/085295 WO2017202264A1 (zh) 2016-05-24 2017-05-22 达格列净新晶型及其制备方法和用途

Publications (1)

Publication Number Publication Date
BR112018071991A2 true BR112018071991A2 (pt) 2019-02-12

Family

ID=60412111

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071991-9A BR112018071991A2 (pt) 2016-05-24 2017-05-22 forma de cristal da dapaglifozina e método para a preparação e uso da mesma

Country Status (10)

Country Link
US (1) US10464915B2 (pt)
EP (1) EP3466939B1 (pt)
JP (1) JP7007300B2 (pt)
KR (1) KR20190010578A (pt)
CN (1) CN108699020B (pt)
BR (1) BR112018071991A2 (pt)
ES (1) ES2864153T3 (pt)
MX (1) MX2018013729A (pt)
TW (1) TWI747906B (pt)
WO (1) WO2017202264A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110790735A (zh) * 2018-08-03 2020-02-14 北京海晶生物医药科技有限公司 一种达格列净新晶型n及其制备方法
CN111559997A (zh) * 2019-02-13 2020-08-21 罗欣药业(上海)有限公司 一种达格列净新晶型及其制备方法
CN111689936A (zh) * 2019-03-15 2020-09-22 罗欣药业(上海)有限公司 达格列净新晶型及其制备方法
WO2021176096A1 (en) 2020-03-05 2021-09-10 Krka, D.D., Novo Mesto Pharmaceutical composition comprising sglt2 inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
NZ604897A (en) * 2008-08-22 2014-03-28 Theracos Sub Llc Processes for the preparation of sglt2 inhibitors
CN103889429B (zh) * 2011-10-31 2016-10-19 台湾神隆股份有限公司 Sglt2抑制剂的结晶和非结晶形式
US8952139B2 (en) * 2011-11-07 2015-02-10 Scinopharm Taiwan, Ltd Process for the preparation of β-C-aryl glucosides
EP2597090A1 (en) 2011-11-28 2013-05-29 Sandoz AG Crystalline dapagliflozin hydrate
CN104829572B (zh) * 2014-02-10 2019-01-04 江苏豪森药业集团有限公司 达格列净新晶型及其制备方法
CN104829573B (zh) * 2014-02-11 2018-09-07 江苏豪森药业集团有限公司 达格列净晶型及其制备方法
CN106543124A (zh) * 2015-09-18 2017-03-29 天津市汉康医药生物技术有限公司 达格列净化合物

Also Published As

Publication number Publication date
US10464915B2 (en) 2019-11-05
CN108699020B (zh) 2021-10-15
ES2864153T3 (es) 2021-10-13
CN108699020A (zh) 2018-10-23
WO2017202264A1 (zh) 2017-11-30
EP3466939A4 (en) 2019-12-18
MX2018013729A (es) 2019-05-02
US20190218197A1 (en) 2019-07-18
KR20190010578A (ko) 2019-01-30
JP7007300B2 (ja) 2022-01-24
TWI747906B (zh) 2021-12-01
EP3466939B1 (en) 2021-02-24
JP2019516706A (ja) 2019-06-20
TW201741327A (zh) 2017-12-01
EP3466939A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
SV2018005771A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
DOP2017000109A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112019006194A2 (pt) composições que compreendem um ligante de ligação ao receptor de canabinóides
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112014016808A2 (pt) composições de biguanida e métodos de tratamento de distúrbios metabólicos
BR112018071991A2 (pt) forma de cristal da dapaglifozina e método para a preparação e uso da mesma
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
NI201500096A (es) Compuesto químicos
EA201690159A1 (ru) Способы и композиции для лечения рака
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
UY37221A (es) Derivados de feniltriazol sustituidos con amida y usos de estos
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
PE20171243A1 (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados
BR112017028616A2 (pt) acentuador de inibidores de homólogo de zeste 2
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
EA201791875A1 (ru) Комбинированная композиция тезофензина и бета-блокатора

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2724 DE 21/03/2023.